



February 3, 2024

BSE Limited
Floor 25, P. J. Towers
Dalal Street,
Mumbai - 400 001

Scrip Code: 530019

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 051

Symbol: JUBLPHARMA

Dear Sirs,

We enclose a communication pursuant to Provisions of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We request you to take the same on record.

Thanking you,
Yours faithfully,

For **Jubilant Pharmova Limited**

Naresh Kapoor
Company Secretary
Encl.: As above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624



Jubilant Pharmova Limited

1A, Sector 16A, Noida – 201301, India

Tel.: +91 120 4361000

www.jubilantpharmova.com

Jubilant Pharmova announces completion of USFDA audit of Solid dosage manufacturing facility at Roorkee, India

Noida, Feb 3, 2024, Jubilant Pharmova Limited announced that the United States Food and Drug Administration (USFDA) has concluded audit of the solid dosage formulations facility on February 2, 2024 at Roorkee site, India of Jubilant Generics Limited ('Company'), a subsidiary of its wholly owned subsidiary Jubilant Pharma Limited.

The USFDA has issued 4 observations pursuant to the completion of audit. The company will submit an action plan on the observations.

The company currently supplies only one product to US from Roorkee facility, that contributed less than one percent of Jubilant Pharmova's 9M'FY24 revenues.

About Jubilant Pharma Limited

Jubilant Pharma Limited (JPL), a Company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Pharmova Limited, is an integrated global pharmaceutical company engaged in manufacturing and supply of Radiopharmaceuticals with a network of 46 radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Solid Dosage Formulations through five manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. The Company has a team of around 3,200 multicultural people across the globe and is committed to delivering value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally. For more info please visit www.jubilantpharma.com

About Jubilant Pharmova Limited

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is engaged in Radiopharma, Allergy Immunotherapy, CDMO of Sterile Injectable, Generics, Contract Research Development and Manufacturing (CRDMO) and Proprietary Novel Drugs businesses. With a network of 46 radio-pharmacies in the US, Jubilant's Radiopharma business is engaged in manufacturing and supply of Radiopharmaceutical products and services. Its other businesses such as Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Generics (Solid Dosage Formulations) caters to major regulated markets (USA, EU and other geographies) through five manufacturing facilities. The CRDMO segment (through Jubilant Biosys) provides collaborative research and partnership for Drug Discovery through two world class research centers in India. The company is also involved in the manufacturing of Active Pharmaceutical Products (API) through a US FDA approved facility in Nanjangud, Karnataka. Jubilant Therapeutics (JTI) invested for in-house Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Pharmova Limited has a team of over 5,500 multicultural people across the globe. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals companies globally. For more information, please visit: www.jubilantpharmova.com



For more information, please contact:

For Investors

Pankaj Dhawan

Phone: +91 120 436 1105

E-mail: Pankaj.dhawan@jubl.com

Siddharth Rangnekar

CDR India

Phone: +91 97699 19966

E-mail: siddharth@cdr-india.com

For Media

Sudhakar Safaya

Phone: +91-120 436 1062

E-mail: sudhakar.safaya@jubl.com

Ryan Marshall

Madison Public Relations

Phone: +91 9810047944

E-mail: ryan.marshall@madisonpr.in

Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

